In November 2015, the company said it had received a warning letter from the US Food and Drug Administration (USFDA) for three of its sites -- active pharmaceutical ingredient (API) manufacturing facilities at Srikakulum, Andhra Pradesh, and Miryalguda, Telengana, and Oncology formulation manufacturing facility at Duvadda, Visakhapatnam, Andhra Pradesh.USFDA ‘closes#39; warning letter for three sites of Dr Reddy#39;s Laboratories
In November 2015, the company said it had received a warning letter from the US Food and Drug Administration (USFDA) for three of its sites -- active pharmaceutical ingredient (API) manufacturing facilities at Srikakulum, Andhra Pradesh, and Miryalguda, Telengana, and Oncology formulation manufacturing facility at Duvadda, Visakhapatnam, Andhra Pradesh.
Subscribe to:
Post Comments (Atom)
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
-
In July, HCL Technologies had announced a Rs 4,000 crore buyback programme for FY19 at a price of Rs 1,100 per equity share.
No comments:
Post a Comment